ArticleFrontiers in pharmacology2026
Investigation of the improvement effect of Dajianzhong decoction on rats with post-operative ileus based on serum metabolomics and spectrum-effect relationship.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Postoperative ileus (POI) is a common complication following abdominal surgery, with limited preventive and therapeutic strategies. Dajianzhong Decoction (DJZD), a classic formula in traditional Chinese medicine, has demonstrated clinical potential in alleviating POI, yet its underlying composition and molecular mechanisms remain to be systematically elucidated. Methods: HPLC fingerprinting was performed on 30 batches of DJZD, and spectrum-effect correlation analysis was conducted by correlating fingerprint data with 5-HT secretion levels in RIN-14B cells. A rat POI model was established to compare the effects of preoperative preventive and postoperative therapeutic administration of DJZD on gastrointestinal motility. Serum untargeted metabolomics was employed to identify differentially expressed metabolites and analyze relevant metabolic pathways. Results: Eleven key metabolite from DJZD were screened and confirmed, namely, ginsenoside Rg Conclusion: DJZD alleviates POI through multi-component, multi-pathway mechanisms involving the modulation of intestinal 5-HT signaling and systemic metabolic reprogramming. This study provides a pharmacological basis for the clinical use of DJZD in POI and exemplifies the holistic regulatory characteristics of traditional Chinese medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.